(Parte 4 de 4)

Goodman and Gilman‘s. The pharmacological basis of therapeutics. 9ed. New York: Mc Graw-Hill, 1996:617-58. 8.Clements PJ, Paulus HE. Nonsteroidal antirheumatic drugs. In: Kelley, et al (eds). Textbook of Rheuamtology, 5ed, Philadelphia, WB Saunders, 1997;707-40. 9.Schelger SI. General characteristics of nonsteroidal anti-inflammatory drugs. In: Paulus HE, Flerst DE, Drongode‘s (eds). Drugs for rheumatic disease. New York, Churchill. Levingstone, 1987, 203. 10.Maher, JF. Analgesic Nephropaty. Am. J. Med 1984; 76: 345-348. 1.Clive DM & Stoff JF.Renal Syndromes Associated with Nonsteroid

Anti-inflammatory Agents. N. Engl. J. Med 1984; 310: 563-572. 12.Hardaman JG, Limbird LE. Goodman & Gilman’s As Bases Farmacológicas da Terapêutica. 10ª ed. cap. 26. S. Paulo: McGraw-Hill, 2002. 13.Griec, C.R e Stitzel, R.E. Farmacologia Moderna com aplicações clínicas. 6 ed. cap.36. Rio de Janeiro: Guanabara Koogan, 2005. 14.Wolfe MN; Lichtenstein DR; Singh G. Gastrointestinal Toxicity of Nonsteroidal Anti-inflammatory Drugs. N Eng J Med 199;340:1888-9. 15.Papatheodoridis GV; Sougioultzis S; Archimandritis AJ. Effects of

Helicobacter pylori and Nonsteroidal Anti-Inflammatory Drugs on Peptic Ulcer Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2006 Feb;4(2):130-42. 16.Howkey, CJ. Nonsteroidal anti-inflammatory drugs and peptic ulcers.

Br Med J 1990;300:278-84. 17.Yeormans ND; Tulassay Z; Juhász L; et al. A comparision of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998; 338:719-26. 18.Fuchs FD; Wannmacher L. Farmacologia clínica. 2 ed. Rio de Janeiro:

B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvein TK, Schnitzer TJ: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520-1528. 21.Silverstein FE, Faich G, Goldstein JL, Simons LS, Pincus T, Whelton

A, Makuch R, Eisen G, Agrawal NM, Stenson WF, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247-1255. 2.Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK,

Oxenius B: The gastrointestinal safety of the COX-2 selectiveninhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003, 98:1725-1733. 23.Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW,

Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet 2004, 364:675-84. 24.Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ,To

KF, Leung WK, Wong VW, et al.: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002, 347:2104-2110. 25.Feldman, MD. NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity. UpToDate June 2007. 26.Estes L; Fuhs DW; Heaton AH; Butwinick CS. Gastric ulcer perforation associated with the use of injectable ketorolac. Ann Pharmacother 1993 Jan;27(1):42-3. 27.Wolfe PA; Polhamus CD; Kubik C; Robinson AB; Clement DJ.Giant duodenal ulcers associated with the postoperative use of ketorolac: report of three cases.Am J Gastroenterol 1994 Jul; 89(7):1110-1. 28.Blot WJ; McLaughlin JK .Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat 2000; 5(2):137-42. 29.Wallace JL; Miller MJ. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology 2000 Aug; 119(2):512-20. 30.Fiorucci S; Santucci L; Gresele P; Faccino RM; Del Soldato P; Morelli

A Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003

TEMAS DE REUMATOLOGIA CLÍNICA - VOL. 9 - Nº 2 - MAIO DE 200862

Mar; 124(3):600-7. 31.Cryer B; Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999 Jul; 117(1):17-25. 32.Lanza FL. A guideline for the treatment and prevention of NSAID- induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998 Nov; 93(1):2037-46. 3.FitzGerald GA. COX-2 and beyond; approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003, London; (2): 879-90. 34.Schnitzer TJ et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications:randomized controlled trial. Lanat 2004. London; (364): 665-74. 35.Farkouh ME. et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes randomized controlled trial. Lancet 2004. London;(364): 674-84. 36.Saraiva JFK. COX-2 Risco Cardiovascular: efeito molécula ou classe dependente? Phaoenix Comunicação Integrada, 2007.São Paulo: 1-5. 37.Bombardier C, et AL. Comparision of upper gastrointestinal toxicity of rofecoxibe and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000, Boston; (343): 1520-8. 38.Silverstain FE, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs of osteoarthritis and rheumatoid arthritis: the CLASS study: randomized controlled trial. Celecoxib Longterm Arthritis Safety Study. JAMA 2000, Chicago; (284): 1247-5. 39.Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan

K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352(1): 1092-102. 40.Ott E, et al. Efficacy and safety of the cyclooxigenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; (125):1481-92. 41.Valdecoxib. WHO Pharmaceuticals Newsletter 2004. Geneva;(6):4. 42.Mandani M et.al. Cyclooxigenase-2 inhibitors versus non selective nonsteroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004. London; (363):1751-6.

43.Gottlieb S. Warnings issued over COX-2 inhibitors in US and UK. BMJ, 2005. London; (330): 9. 4.US Department of Health and Human Services. NIH halts use of COX- 2 inhibitor in large cancer prevention trial. NIH News 2004. 45.FDA statement ou naproxen. Disponível em: http//w.fda.gov/bbs/ topics/news/2004/NEW01148.htmal 46.Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368:1771. 47.Rose BD. NSAIDs: Acute renal failure and nephrotic syndrome.

UpToDate. June 2007. 48.Huerta C; Castellsague J; Varas-Lorenzo C; Garcia Rodriguez LA.

Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005;(3):531-9. 49.Braden GL; O’Shea MH; Mulhern JG; Germain MJ. Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors. Nephrol Dial Transplant 2004;(5):1149-53. 50.Alper AB Jr; Meleg-Smith S; Krane NK. Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kidney Dis 2002;(5):1086-90. 51.Neilson EG. Pathogenesis and therapy of interstitial nephritis. Kidney

Int 1989; (5):1257-70. 52.Rostom A; Goldkind L; Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005; (5):489-98. 53.Scully LJ; Clarke D; Barr RJ. Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993; 38(4):744-51. 54.Goodwin SD; Glenny RW. Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports. Arch Intern Med 1992; 152(7):1521-4. 5.Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330(18):1287-94. 56.Characteristics of meningitis caused by Ibuprofen: report of 2 cases with recurrent episodes and review of the literature. Medicine (Baltimore) 2006; 85(4):214-20. 57.Solomon DH. NSAIDs: Overview of adverse effects. UpToDate June 2007.

TEMAS DE REUMATOLOGIA CLÍNICA - VOL. 9 - Nº 2 - MAIO DE 200863

(Parte 4 de 4)

Comentários